ORIC - ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

2024-03-13 08:19:27 ET

Summary

• ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline: ORIC-944, ORIC-114, and ORIC-533.
• ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first half of 2024 and provide a program update in mid-2024.
• The global prostate cancer market size is projected to surpass $27.51 billion by 2032.
• ORIC had $235 million in cash as of December 31st, 2023. It believes that it has enough cash on hand to fund its operations into 2026.

ORIC Pharmaceuticals ( ORIC ) has already reported preliminary results for three programs in its pipeline, which are: ORIC-944, ORIC-114 and ORIC-533. With respect to ORIC-944 for the treatment of patients with metastatic prostate cancer, several positive developments were reported from the phase 1b monotherapy study. There are two catalysts to which investors can keep an eye on, which might generate shareholder value. The first of which would be initiation of the phase 1/2 combination study, using ORIC-944 in combination with an Androgen Receptor [AR] inhibitor for the treatment of this patient population, expected in the 1st half of 2024. From there, an even bigger catalyst is expected to emerge, which would be a program update that is expected to happen in mid-2024....

For further details see: